COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00029224
Recruitment Status : Completed
First Posted : January 10, 2002
Last Update Posted : February 1, 2012
Information provided by (Responsible Party):

Brief Summary:
Patients with bone metastases or bone lesions caused by breast cancer, multiple myeloma or prostate cancer will be treated with IV Zometa in a 15 minute infusion. Pain will be evaluated, as well as time in chair, quality of life and safety of Zometa.

Condition or disease Intervention/treatment Phase
Breast Cancer Multiple Myeloma Prostate Cancer Drug: zoledronic acid Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 500 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions
Study Start Date : October 2001
Actual Primary Completion Date : November 2002
Actual Study Completion Date : November 2002

Primary Outcome Measures :
  1. Pain score assessed by change from baseline

Secondary Outcome Measures :
  1. Quality of life
  2. Time in infusion chair
  3. Safety assessed by adverse events (AEs)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Signed informed consent
  • Greater than 18 years of age
  • Proof of breast cancer, multiple myeloma or prostate cancer
  • Diagnosis of at least one cancer-related bone lesion
  • If patient is of child-bearing potential, negative pregnancy test and on a medically recognized form of contraception
  • ECOG performance status of 0,1 or 2
  • Ability to read, understand and write English or Spanish language
  • Normal renal function
  • Corrected serum calcium equal to or greater than 8mg/dl Exclusion Criteria
  • clinically symptomatic brain metastases
  • hypersensitivity to Zometa or other bisphosphonates
  • pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00029224

Layout table for location information
United States, California
Stockton Hematology Oncology Medical Group
Stockton, California, United States, 95204
United States, Florida
Osceola Cancer Center
Kissimmee, Florida, United States, 34741
United States, Nevada
Nevada Cancer Center
Las Vegas, Nevada, United States, 89109
United States, New Mexico
Hematology-Oncology Associates PC
Albuquerque, New Mexico, United States, 87102
New Mexico Oncology Hematology Consultants
Albuquerque, New Mexico, United States, 87102
United States, Oregon
Hematology Oncology Associates, PC
Medforo, Oregon, United States, 97504
United States, Virginia
Virginia Physicians, Inc
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Novartis Identifier: NCT00029224    
Other Study ID Numbers: CZOL446EUS16
First Posted: January 10, 2002    Key Record Dates
Last Update Posted: February 1, 2012
Last Verified: January 2012
Keywords provided by Novartis:
bone lesions
breast cancer
multiple myeloma
prostate cancer
bone metastases
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Prostatic Neoplasms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Site
Breast Diseases
Skin Diseases
Genital Neoplasms, Male
Urogenital Neoplasms
Prostatic Diseases
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Zoledronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs